Spots Global Cancer Trial Database for chidamide
Every month we try and update this database with for chidamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | NCT04040491 | Peripheral T-ce... | PD-1 blocking a... | 14 Years - 65 Years | Zhengzhou University | |
| Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety | NCT02883374 | Adenocystic Car... | Chidamide | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| Chidamide Bridging for CAR-T Therapy | NCT05370547 | Non Hodgkin's L... | Chidamide Fludarabine and... Anti-CD19 CAR-T... | 16 Years - 75 Years | Chinese PLA General Hospital | |
| Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | NCT03617432 | Experimental Tu... | Chidamide Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone | 18 Years - 70 Years | Peking University | |
| Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | NCT04337606 | Non Hodgkin Lym... | Chidamide Decitabine Camrelizumab | 18 Years - 65 Years | Chinese PLA General Hospital | |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | NCT03564704 | Leukemia Leukemia, Acute Adult Lymphobla... Leukemia, Lymph... Leukemia, T Cel... Adult Acute Lym... Lymphoblastic L... Lymphoblastic L... | Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping Chidamide PET-CT scan | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | NCT05823701 | Diffuse Large B... | Chidamide Azacitidine obinutuzumab Liposomal mitox... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) | NCT03268889 | Peripheral T Ce... | Chidamide | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | NCT06218888 | Colo-rectal Can... | Tislelizumab Fruquintinib Chidamide | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma | NCT02753543 | Peripheral T Ce... | Chidamide | 16 Years - 75 Years | Ruijin Hospital | |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT03373019 | Chidamide Lymphoma, B-Cel... Lymphoma, Large... Neoplasm by His... Neoplasms Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Cyclophosphamid... Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor | Chidamide combi... | 18 Years - 75 Years | Fudan University | |
| Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma | NCT04511351 | Lymphoma | Chidamide | 18 Years - | ChineseAMS | |
| Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | NCT03974243 | Non-hodgkin's L... | Chiauranib Chidamide | 18 Years - 70 Years | Chipscreen Biosciences, Ltd. | |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | NCT03564470 | Leukemia Leukemia, Acute Leukemia, Lymph... Leukemia, B-cel... | Chidamide Dasatinib | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Chidamide Plus R-CHOP in Elderly DLBCL | NCT02753647 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Chidamide | 61 Years - 75 Years | Ruijin Hospital | |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | NCT05367856 | T Cell Lymphoma | Chidamide combi... | 18 Years - 65 Years | Ruijin Hospital | |
| Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma | NCT02753543 | Peripheral T Ce... | Chidamide | 16 Years - 75 Years | Ruijin Hospital | |
| Biomarker Guided Treatment in DLBCL | NCT04025593 | Diffuse Large B... | Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Ibrutinib Lenalidomide chidamide decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | NCT02809573 | Peripheral T-ce... | Chidamide cyclophosphamid... adriacin vincristine prednisone | 18 Years - 65 Years | Chipscreen Biosciences, Ltd. | |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | NCT03023358 | Peripheral T Ce... | chidamide cyclophosphamid... liposomal doxor... vincristine prednisone | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib | NCT05464173 | Breast Cancer | Chidamide Abemaciclib endocrinotherap... | 18 Years - | Fudan University | |
| Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma | NCT02944812 | Peripheral T Ce... | Chidamide | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | NCT05179213 | Angioimmunoblas... | Azacitidine Chidamide | 18 Years - | Peking Union Medical College Hospital | |
| Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | NCT03410004 | Experimental | Chidamide | 18 Years - 75 Years | ChineseAMS | |
| Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | NCT05572983 | Peripheral T-Ce... | Chidamide combi... Chidamide | 18 Years - 75 Years | Sun Yat-sen University | |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | NCT05068427 | Non Small Cell ... | Chidamide Envafolimab | 18 Years - | Chipscreen Biosciences, Ltd. | |
| Efficacy and Safety of Chidamide in CBF Leukemia | NCT03031262 | AML | Cytarabine Chidamide | 14 Years - 55 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma | NCT02987244 | T Cell Non-Hodg... | Chidamide Cyclophosphamid... Epirubicin Vindesine Etoposide Prednisone | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | NCT03853044 | Angioimmunoblas... | Chidamide Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | Ruijin Hospital | |
| Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety | NCT02883374 | Adenocystic Car... | Chidamide | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) | NCT05976997 | Newly Diagnosed... | Duvelisib, Chid... | 18 Years - 70 Years | Huazhong University of Science and Technology | |
| Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma | NCT03611231 | Experimental Tu... | Chidamide | 18 Years - 70 Years | Peking University | |
| Efficacy and Safety of Chidamide in CBF Leukemia | NCT03031262 | AML | Cytarabine Chidamide | 14 Years - 55 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | NCT03553238 | Leukemia, Acute Leukemia, T Cel... Leukemia, Lymph... | Chidamide Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-Mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL | NCT04831710 | Angioimmunoblas... | Sintilimab Chidamide | 18 Years - 75 Years | Sun Yat-sen University | |
| Chidamide in Patients With Recurrent and Refractory Diffuse Large b | NCT05690191 | Diffuse Large B... | Chidamide Lenalidomide Rituximab | 18 Years - | Second Affiliated Hospital of Soochow University | |
| Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | NCT01836679 | Non-small-cell ... | Chidamide Paclitaxel Carboplatin Placebo | 18 Years - 75 Years | Chipscreen Biosciences, Ltd. | |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | NCT03553238 | Leukemia, Acute Leukemia, T Cel... Leukemia, Lymph... | Chidamide Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-Mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | NCT03974243 | Non-hodgkin's L... | Chiauranib Chidamide | 18 Years - 70 Years | Chipscreen Biosciences, Ltd. | |
| Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) | NCT05281276 | Metastatic Colo... | chidamide celecoxib | 20 Years - | Taipei Medical University Shuang Ho Hospital | |
| Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | NCT06386302 | AML Acute Myeloid L... | Chidamide Venetoclax azacitidine | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT02733380 | Diffuse Large B... | Chidamide Vinorelbine Liposomal Doxor... Dexamethasone Thalidomide | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | NCT03853044 | Angioimmunoblas... | Chidamide Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | Ruijin Hospital | |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | NCT05823701 | Diffuse Large B... | Chidamide Azacitidine obinutuzumab Liposomal mitox... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | NCT04724239 | Advanced Micros... Metastatic Micr... | Sintilimab Chidamide IBI305 | 18 Years - 75 Years | Sun Yat-sen University | |
| Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC | NCT05400993 | Breast Cancer | Chidamide | 18 Years - 75 Years | Shengjing Hospital | |
| Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | NCT04480125 | Peripheral T-ce... | Azacitidine Chidamide | 18 Years - | Ruijin Hospital | |
| Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) | NCT03273452 | Angioimmunoblas... | Chidamide | 18 Years - 75 Years | Qingdao University | |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | NCT05068427 | Non Small Cell ... | Chidamide Envafolimab | 18 Years - | Chipscreen Biosciences, Ltd. | |
| Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors | NCT03494634 | Experimental Tu... | Chidamide | 18 Years - 70 Years | Sun Yat-sen University | |
| Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse | NCT05270200 | Leukemia, Myelo... | Azacitidine Chidamide | 18 Years - 60 Years | Zhujiang Hospital | |
| New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT05029141 | Acute Myeloid L... Refractory Acut... Relapsed Adult ... | CAHAG regimen Placebo regimen | 18 Years - 69 Years | The First Affiliated Hospital of Soochow University | |
| Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | NCT05566054 | Acute Monocytic... Newly Diagnosed | Chidamide Azacitidine Venetoclax | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | NCT04724239 | Advanced Micros... Metastatic Micr... | Sintilimab Chidamide IBI305 | 18 Years - 75 Years | Sun Yat-sen University | |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | NCT06087419 | Acute Lymphobla... | chidamide Venetoclax Oral... Inotuzumab Ozog... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | NCT03023358 | Peripheral T Ce... | chidamide cyclophosphamid... liposomal doxor... vincristine prednisone | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | NCT05823701 | Diffuse Large B... | Chidamide Azacitidine obinutuzumab Liposomal mitox... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | NCT02878278 | Lymphoma, Extra... EBV | Chidamide BIW Chidamide QD | 18 Years - 75 Years | Sun Yat-sen University | |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | NCT04040491 | Peripheral T-ce... | PD-1 blocking a... | 14 Years - 65 Years | Zhengzhou University | |
| Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | NCT04233294 | Hodgkin Lymphom... | Chidamide Camrelizumab Decitabine | 12 Years - 75 Years | Chinese PLA General Hospital | |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT02733380 | Diffuse Large B... | Chidamide Vinorelbine Liposomal Doxor... Dexamethasone Thalidomide | 18 Years - 75 Years | Henan Cancer Hospital | |
| Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | NCT04480125 | Peripheral T-ce... | Azacitidine Chidamide | 18 Years - | Ruijin Hospital | |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | NCT05823701 | Diffuse Large B... | Chidamide Azacitidine obinutuzumab Liposomal mitox... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer | NCT05047848 | Advanced Breast... | Chidamide Fulvestrant | 18 Years - | Liaoning Tumor Hospital & Institute | |
| Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer | NCT02482753 | Breast Cancer | Chidamide exemestane placebo | 18 Years - 75 Years | Chipscreen Biosciences, Ltd. | |
| Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors | NCT03494634 | Experimental Tu... | Chidamide | 18 Years - 70 Years | Sun Yat-sen University | |
| CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT03985007 | Acute Myeloid L... | CDIAG regimen | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) | NCT03268889 | Peripheral T Ce... | Chidamide | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma | NCT03151876 | Lymphoma | Chidamide Cladribine gemcitabine Busulfan Autologous hema... | 18 Years - 60 Years | Sichuan University | |
| Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | NCT05330364 | Acute Myeloid L... | Chidamide Cladribine | 18 Years - 75 Years | Zhongda Hospital | |
| Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | NCT04337606 | Non Hodgkin Lym... | Chidamide Decitabine Camrelizumab | 18 Years - 65 Years | Chinese PLA General Hospital | |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma | NCT03602131 | Hodgkin Lymphom... Non-hodgkin Lym... | Chidamide Cladribine gemcitabine Busulfan Autologous hema... | 15 Years - 65 Years | Sichuan University | |
| ChiCGB vs BEAM in High-risk or R/R Lymphomas | NCT05466318 | Lymphoma, Large... Lymphoma, T-Cel... | Chidamide Cladribine Gemcitabine Busulfan Carmustine Etoposide Cytarabine Melphalan Autologous hema... | 16 Years - 65 Years | Sichuan University | |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | NCT05179213 | Angioimmunoblas... | Azacitidine Chidamide | 18 Years - | Peking Union Medical College Hospital | |
| Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma | NCT02987244 | T Cell Non-Hodg... | Chidamide Cyclophosphamid... Epirubicin Vindesine Etoposide Prednisone | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL | NCT04052659 | Peripheral T-ce... | Sintilimab Chidamide Azacidine | 18 Years - 80 Years | Peking University | |
| Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | NCT04724239 | Advanced Micros... Metastatic Micr... | Sintilimab Chidamide IBI305 | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL | NCT03245905 | Relapsed or Ref... | Chidamide | 18 Years - 75 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
